Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
Status:
Completed
Trial end date:
2021-07-27
Target enrollment:
Participant gender:
Summary
The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with
primary T-cell lymphoma that is refratory to or has relapsed following initial treatment.